Amir Qureshi, MD
Infectious Disease · Las Vegas, NVNPI 1972538247
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 56.6% of the total. Reporting peaked in 2022 at $552 and has fallen 53.3% since, to $258 in 2025.
Across 65 payments — averaging $30.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Merck$253
- Abbott$171
- Shionogi Inc$144
- Melinta Therapeutics, LLC$134
- Boston Scientific$125
- plus $40 from 2 others
What the payments were for
- Food & beverage$1,98799%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $1,131 |
| Merck | 8 | $253 |
| Abbott | 1 | $171 |
| Shionogi Inc | 2 | $144 |
| Melinta Therapeutics, LLC | 7 | $134 |
| Boston Scientific | 1 | $125 |
| Insmed, Inc. | 1 | $20 |
| Fisher Scientific Company L.L.C. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Proclaim IPG$171
- Watchman$125
- AVYCAZ$125
- Fetroja$123
- EMBLAVEO$117
How this compares
$1,999 in reported general payments places this provider in the 55th percentile of 65 infectious disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 146 | $218,202 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 22 | $92,846 |
| ErtapenemErtapenem Sodium | 58 | $27,397 |
| Meropenem | 46 | $7,551 |
| Cefepime Hcl | 41 | $6,534 |
| CeftriaxoneCeftriaxone Sodium | 131 | $5,340 |
| Rifabutin | 14 | $4,891 |
| Cefazolin Sodium | 29 | $1,103 |
| Vancomycin Hcl | 15 | $964 |
| Doxycycline Hyclate | 27 | $944 |
| Ethambutol Hcl | 22 | $824 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $289 |
| Fluconazole | 16 | $171 |
| Cephalexin | 12 | $156 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Las Vegas
- Alireza FarabiLas Vegas$588K
- Dhiresh JoshiLas Vegas$96K
- Shaker ItaniLas Vegas$52K
- Dhaval ShahLas Vegas$27K
- Alka RebentishLas Vegas$23K
- Ronald ShockleyLas Vegas$13K
- Chukwudum UcheLas Vegas$13K
- John OreillyLas Vegas$8K
- Li-Chien ChenLas Vegas$8K
- Naima ZaheerLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.